Medicines and Health Products, Sciensano, Juliette Wytsmanstraat 14, 1050, Brussels, Belgium.
Medicines and Health Products, Sciensano, Juliette Wytsmanstraat 14, 1050, Brussels, Belgium.
Regul Toxicol Pharmacol. 2019 Apr;103:106-112. doi: 10.1016/j.yrtph.2019.01.022. Epub 2019 Jan 16.
Personal lubricants and lubricants used in condoms contain a number of ingredients which are also present in cosmetic products. These have to comply to the medical device regulation (745/2017) which should provide the same level of consumer protection, if not more, as foreseen in the legal framework of cosmetics (1223/2009). In the current study we developed an analytical method capable of identifying and quantifying 15 ingredients, commonly found in lubricants and cosmetics. Based upon their most important toxicological endpoint, the substances involved were grouped in three toxicological classes provoking either irritation, contact allergic dermatitis or systemic toxicity. The method was applied on 30 condoms and 54 personal lubricants present on the EU market. Their safety was assessed using the same reasoning as commonly applied for cosmetic ingredients. Higher mucosae susceptibility, the main exposed area for lubricants, was taken into account in this assessment. The results show that the majority of the products studied are safe. Nevertheless, for some products the safety could not be confirmed. The results also highlight the fact that there is no consensus for a number of ingredients, used as well in cosmetics as in medical devices. Alignment between both legislations would improve the safety of these products and further raise the general level of consumer protection.
个人润滑剂和避孕套用润滑剂中含有许多成分,这些成分也存在于化妆品中。这些成分必须符合医疗器械法规(745/2017)的规定,如果不比化妆品(1223/2009)的法律框架更能提供相同水平的消费者保护,则应符合该法规。在目前的研究中,我们开发了一种能够识别和定量分析 15 种常见于润滑剂和化妆品中的成分的分析方法。根据它们最重要的毒理学终点,将涉及的物质分为引起刺激、接触性过敏性皮炎或全身毒性的三种毒理学类别。该方法应用于欧盟市场上的 30 个避孕套和 54 个个人润滑剂。使用与通常应用于化妆品成分相同的推理来评估它们的安全性。在这种评估中,考虑了更高的黏膜易感性,这是润滑剂的主要暴露区域。研究结果表明,研究的大多数产品是安全的。然而,对于一些产品,安全性无法得到确认。结果还强调了这样一个事实,即有一些成分在化妆品和医疗器械中都有使用,但尚未达成共识。这两种法规之间的协调将提高这些产品的安全性,并进一步提高消费者的总体保护水平。